Talk: Application of artificial intelligence in the management of Parkinson’s disease
Prof. Lingjing Jin is a long-term distinguished professor in Neurology at School of Medicine, Tongji University, China. He is president of Shanghai Yangzhi Rehabilitation Hospital, School of Medicine, Tongji University. He took his specialization in Neurology and PhD in Neuroscience at Hannover Medical School, Germany. After that, he further specialized on movement disorders by leading researches focused on the diagnosis and treatment of movement disorders and development of new technologies for neurological rehabilitation, especially botulinum toxin therapy.
By studying the pathological basis of abnormal neural regulatory circuits in movement disorders, he has discovered a number of novel intervention targets for the progressive loss of dopaminergic neurons. Moreover, he designed a gene therapy candidate drug that could regulate the expression of mesencephalic astrocyte-derived neurotrophic factor (MANF). He developed new technologies for central regulation and peripheral intervention by establishing a new multimodal rehabilitation training strategy to improve balance function of patients with Parkinson’s disease and developing a series of new technologies and devices for botulinum toxin to control local spasm and dystonia, with which he completed the world’s first treatment of diaphragmatic clonus (an intractable movement disorder). He is the first author or corresponding author (including co-first or co-corresponding author) of more than 60 publications in international journals, including publications in Nature Struct Mol Biol, Proc Natl Acad Sci USA, Redox Biol, Movement Disorders, and npj Parkinson’s Disease, etc.